Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This article reviews the characteristics and uses of finasteride for benign prostatic hyperplasia, noting variable symptom improvement and ongoing investigation in other DHT-mediated conditions, and reports no new clinical results.

This study found that a bleach bath treatment with 0.005% HOCI reduced the expression of certain serine proteases in cultured keratinocytes and lowered skin pH in atopic dermatitis patients, potentially improving symptoms by modulating the NF-kB pathway.

This review found that intralesional corticosteroid injections and 5-alpha-reductase inhibitors were reported as the most effective treatments for frontal fibrosing alopecia, with oral isotretinoin showing promise for facial papule improvement.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This editorial response discusses the evidence for using 5-alpha reductase inhibitors in treating frontal fibrosing alopecia, acknowledging its potential benefits while emphasizing the need for further studies to establish it as a standard treatment.

The flutamide-loaded hydrogel is a promising, skin-friendly treatment for acne and hair loss, potentially requiring less frequent application.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This systematic review concluded that 5 mg of oral finasteride per day could be an effective and safe treatment for female pattern hair loss in normoandrogenic women, particularly when combined with other medications.

The topical finasteride spray was safe and well-tolerated with stable effects.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

In this study, black cumin oil-based nanostructured lipid carriers enhanced the delivery and effectiveness of fluticasone for psoriasis in a mouse model, improving skin targeting, inflammation reduction, and permeability compared to standard cream.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

Taking 5 mg/day finasteride can cause side effects in women with hair loss, but these are usually mild and fade over time, making the treatment beneficial in the long run.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this study, the Trivedi Effect®-Consciousness Energy Healing Treatment was reported to significantly increase the solubility and isotopic abundance ratios of flutamide, potentially improving its stability and efficacy.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

In this case study, a 34-year-old woman experienced facial allergic reactions to SPF-containing products, and patch tests identified sensitization to salicylates, which when avoided, stabilized her symptoms and her existing frontal fibrosing alopecia, highlighting a possible link to investigate further.

This article outlines a treatment protocol for frontal fibrosing alopecia using finasteride or dutasteride and minoxidil, but reports no new clinical results.

In this case report, a 75-year-old man with benign essential blepharospasm and Parkinson disease experienced significant symptom relief from dystonia after starting finasteride, suggesting it may be a potential therapeutic option.

This study observed that 62% of premenopausal women with female pattern hair loss reported improvement when treated with oral finasteride and an oral contraceptive containing drospirenone and ethinyl estradiol.